Recent

% | $
Quotes you view appear here for quick access.

Puma Biotechnology, Inc. Message Board

  • busy26795 busy26795 May 23, 2013 9:38 AM Flag

    PBYI Puma Biotechnology price target raised to $59 from $40 at BofA/Merrill

    Puma Biotechnology price target raised to $59 from $40 at BofA/Merrill

    PBYI Puma Biotechnology price target raised to $59 from $40 at BofA/Merrill
    BofA/Merrill raised Puma Biotechnology estimates to reflect increased value for tyrosine kinase inhibitor neratinib following management's plans to initiate a "basket study" in order to evaluate neratinib across a large range of solid tumors in patients with activating mutations. The firm believes neratinib could be a $2B+ drug. Shares are Buy rated

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
PBYI
185.61+7.16(+4.01%)May 6 4:02 PMEDT